TUCSON, Ariz.--(BUSINESS WIRE)--March 21, 2006--Vivo Ventures participated in the final close of a $9 million Series A financing co-led by Charter Life Sciences and Research Corporation Technologies. APT Pharmaceuticals is a clinical-stage biopharmaceutical company developing products to treat asthma, chronic pulmonary obstructive disease, rhinitis and rhinovirus infection.
